Novartis reports new Phase III data showing omalizumab significantly improves itch in patients with severe form of chronic skin disease CSU[1] » (Novartis AG)

(Source: Novartis AG) Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU)[1] Omalizumab found to be effective, safe and well tolerated in refractory CSU patients, including those on antihistamines at up to four times the approved dose[1] By Week 12 omalizumab eliminated or suppressed symptoms in more than half of patients who failed multiple therapies; benefit sustained during active treatment[1] Basel, June 26, 2013 - Novartis announced today late-breaking results showing omalizumab met all primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria...